|These are a
selection of the adverse events that were reported with a ≥2%
difference in incidence between study arms. Other adverse events that would
qualify for this table are not present because they are known toxicities of
special interest with bevacizumab and are covered on the next slide.
toxicities listed here occurred more frequently in the bevacizumab arms,
anemia and infection were more common in the control arm than either
|This is also true
for grade ≥3 peripheral edema, which does not qualify for inclusion in
the table, but was also reported at a higher incidence in the control arm
(2.1%) than the bevacizumab arms (1.2% [7.5mg/kg], 0.4% [15mg/kg]).